CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 170 enrolled
Drug / intervention
Epoetin Hospirabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01628120
NCT01628120Phase 3Completed
CompareCT.gov

A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment

Pfizer·interventional·Posted Jun 26, 2012·Updated Mar 18, 2019

In Brief

A Phase 3 clinical trial evaluating Epoetin Hospira for Chronic Renal Failure Requiring Hemodialysis. Completed, enrolled 170 participants across 115 sites.

Detailed Summary

To determine the long term safety in treatment-emergent adverse events (TEAEs) of SC administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Renal Failure Requiring Hemodialysis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 26, 2012
Enrollment StartMay 31, 2012
Primary CompletionFeb 13, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.0 years ago

Interventions

Epoetin Hospirabiological

Subcutaneous(SC) injection